Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer

Prostate cancer (PC) is the second most often diagnosed malignancy in men and one of the major causes of cancer death worldwide. Despite genetic predispositions, environmental factors, including a high-fat diet, obesity, a sedentary lifestyle, infections of the prostate, and exposure to chemicals or...

Full description

Bibliographic Details
Main Authors: Izabela Siemińska, Jarek Baran
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.862416/full
_version_ 1818235721410936832
author Izabela Siemińska
Izabela Siemińska
Jarek Baran
author_facet Izabela Siemińska
Izabela Siemińska
Jarek Baran
author_sort Izabela Siemińska
collection DOAJ
description Prostate cancer (PC) is the second most often diagnosed malignancy in men and one of the major causes of cancer death worldwide. Despite genetic predispositions, environmental factors, including a high-fat diet, obesity, a sedentary lifestyle, infections of the prostate, and exposure to chemicals or ionizing radiation, play a crucial role in PC development. Moreover, due to a lack of, or insufficient T-cell infiltration and its immunosuppressive microenvironment, PC is frequently classified as a “cold” tumor. This is related to the absence of tumor-associated antigens, the lack of T-cell activation and their homing into the tumor bed, and the presence of immunological cells with regulatory functions, including myeloid-derived suppressor cells (MDSCs), regulatory T cells (Treg), and tumor-associated macrophages (TAMs). All of them, by a variety of means, hamper anti-tumor immune response in the tumor microenvironment (TME), stimulating tumor growth and the formation of metastases. Therefore, they emerge as potential anti-cancer therapy targets. This article is focused on the function and role of MDSCs in the initiation and progression of PC. Clinical trials directly targeting this cell population or affecting its biological functions, thus limiting its pro-tumorigenic activity, are also presented.
first_indexed 2024-12-12T11:58:28Z
format Article
id doaj.art-1976753347d54a6eb17df37d12a8763a
institution Directory Open Access Journal
issn 2234-943X
language English
last_indexed 2024-12-12T11:58:28Z
publishDate 2022-07-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj.art-1976753347d54a6eb17df37d12a8763a2022-12-22T00:25:09ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-07-011210.3389/fonc.2022.862416862416Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate CancerIzabela Siemińska0Izabela Siemińska1Jarek Baran2Department of Clinical Immunology, Jagiellonian University Medical College, Cracow, PolandUniversity Centre of Veterinary Medicine, Jagiellonian University - University of Agriculture, Cracow, PolandDepartment of Clinical Immunology, Jagiellonian University Medical College, Cracow, PolandProstate cancer (PC) is the second most often diagnosed malignancy in men and one of the major causes of cancer death worldwide. Despite genetic predispositions, environmental factors, including a high-fat diet, obesity, a sedentary lifestyle, infections of the prostate, and exposure to chemicals or ionizing radiation, play a crucial role in PC development. Moreover, due to a lack of, or insufficient T-cell infiltration and its immunosuppressive microenvironment, PC is frequently classified as a “cold” tumor. This is related to the absence of tumor-associated antigens, the lack of T-cell activation and their homing into the tumor bed, and the presence of immunological cells with regulatory functions, including myeloid-derived suppressor cells (MDSCs), regulatory T cells (Treg), and tumor-associated macrophages (TAMs). All of them, by a variety of means, hamper anti-tumor immune response in the tumor microenvironment (TME), stimulating tumor growth and the formation of metastases. Therefore, they emerge as potential anti-cancer therapy targets. This article is focused on the function and role of MDSCs in the initiation and progression of PC. Clinical trials directly targeting this cell population or affecting its biological functions, thus limiting its pro-tumorigenic activity, are also presented.https://www.frontiersin.org/articles/10.3389/fonc.2022.862416/fullprostate cancermyeloid-derived suppressor cellsimmunosuppressionimmunotherapyanti-tumor immune response
spellingShingle Izabela Siemińska
Izabela Siemińska
Jarek Baran
Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer
Frontiers in Oncology
prostate cancer
myeloid-derived suppressor cells
immunosuppression
immunotherapy
anti-tumor immune response
title Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer
title_full Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer
title_fullStr Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer
title_full_unstemmed Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer
title_short Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer
title_sort myeloid derived suppressor cells as key players and promising therapy targets in prostate cancer
topic prostate cancer
myeloid-derived suppressor cells
immunosuppression
immunotherapy
anti-tumor immune response
url https://www.frontiersin.org/articles/10.3389/fonc.2022.862416/full
work_keys_str_mv AT izabelasieminska myeloidderivedsuppressorcellsaskeyplayersandpromisingtherapytargetsinprostatecancer
AT izabelasieminska myeloidderivedsuppressorcellsaskeyplayersandpromisingtherapytargetsinprostatecancer
AT jarekbaran myeloidderivedsuppressorcellsaskeyplayersandpromisingtherapytargetsinprostatecancer